

Xintela gets product patent in USA for chondrocyte-based products

Xintela today announces that the US Patent and Trademark Office (USPTO) has issued the company's patent application on chondrocyte-based cell therapy products, with validity through 2039.

Xintela's US patent, US 11, 725,188, protects the development and commercialization of chondrocyte-based products that are quality assured using the cell surface markers integrin $\alpha 10\beta 1$ and integrin $\alpha 11\beta 1$. The patent is valid until 2039. Xintela has previously received patents for quality assurance of isolated and expanded chondrocytes in several countries including the US and Japan and also a product patent in Japan.

"We are very pleased with this patent. It demonstrates how we continue to innovate to broaden the use of our integrin markers, in this case, for the development and commercialization of high quality chondrocyte products. In discussions with potential collaboration partners and licensees, we see that this patent can have great value, not least for the development of allogeneic (donated) chondrocyte products", says Xintela's CEO Evy Lundgren-Åkerlund.

Xintela has previously reported on the company's analytical method for chondrocytes, XACT (Xintela Assay for Cell Therapy), which makes it possible to determine the quality and purity of isolated and cultured chondrocytes and develop high quality chondrocyte products for the repair of injured cartilage.

Contacts

Xintela AB (publ)

Evy Lundgren-Åkerlund, CEO

Tel: +46 46 275 65 00

Email: evy@xintela.se

Medicon Village

223 81 Lund, Sweden

www.xintela.se

About Xintela

Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company's cell surface marker integrin $\alpha 10\beta 1$ which is found on mesenchymal stem cells and on certain aggressive cancer cells. The stem cell marker is used to select and quality-assure the patent-protected stem cell product XSTEM®, which is in clinical development for treatment of knee osteoarthritis and difficult-to-heal leg ulcers. The company produces XSTEM for the clinical studies in its GMP-approved manufacturing facility. In cancer therapy, which is run by the wholly owned subsidiary Targinta AB, therapeutic antibodies, targeting integrin $\alpha 10\beta 1$ (First-in-Class) are being developed for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. Xintela conducts its business at Medicon Village in Lund, Sweden, and is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB.

Attachments

[Xintela gets product patent in USA for chondrocyte-based products](#)